Zelira Therapeutics Limited

ASX:ZLD Stock Report

Market Cap: AU$7.3m

Zelira Therapeutics Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Zelira Therapeutics.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth47.8%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Zelira Therapeutics Limited's (ASX:ZLD) CEO Will Probably Find It Hard To See A Huge Raise This Year

Nov 08
Zelira Therapeutics Limited's (ASX:ZLD) CEO Will Probably Find It Hard To See A Huge Raise This Year

Is Zelira Therapeutics (ASX:ZLD) In A Good Position To Invest In Growth?

Jul 14
Is Zelira Therapeutics (ASX:ZLD) In A Good Position To Invest In Growth?

Here's Why Zelira Therapeutics (ASX:ZLD) Must Use Its Cash Wisely

Jan 19
Here's Why Zelira Therapeutics (ASX:ZLD) Must Use Its Cash Wisely

Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?

Sep 25
Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?

Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?

Jun 03
Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?

A Quick Analysis On Zelira Therapeutics' (ASX:ZLD) CEO Compensation

Dec 31
A Quick Analysis On Zelira Therapeutics' (ASX:ZLD) CEO Compensation

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Zelira Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

ASX:ZLD - Analysts future estimates and past financials data (AUD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/20240-37-4-4N/A
3/31/20240-36-5-5N/A
12/31/20230-36-5-5N/A
9/30/20230-21-6-6N/A
6/30/20230-6-7-7N/A
3/31/20231-8-8-8N/A
12/31/20221-10-8-8N/A
9/30/20221-11-9-9N/A
6/30/20222-12-9-9N/A
3/31/20221-11-9-9N/A
12/31/20211-10-9-9N/A
9/30/20211-9-9-9N/A
6/30/20211-9-9-9N/A
3/31/20210-8-9-9N/A
12/31/20200-8-8-8N/A
9/30/20200-8-8-8N/A
6/30/2020N/A-7-7-7N/A
3/31/20200-6-6-6N/A
12/31/20191-4-5-5N/A
9/30/20191-4-4-4N/A
6/30/20191-4-3-3N/A
3/31/20191-3-3-3N/A
12/31/20180-3-3-3N/A
9/30/20180-3-3-3N/A
6/30/20180-2-3-3N/A
3/31/20180-2N/A-3N/A
12/31/20170-2N/A-3N/A
9/30/20170-4N/A-2N/A
6/30/20170-6N/A-2N/A
12/31/20160-5N/A-1N/A
6/30/201600N/A0N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ZLD's forecast earnings growth is above the savings rate (2.6%).

Earnings vs Market: Insufficient data to determine if ZLD's earnings are forecast to grow faster than the Australian market

High Growth Earnings: Insufficient data to determine if ZLD's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if ZLD's revenue is forecast to grow faster than the Australian market.

High Growth Revenue: Insufficient data to determine if ZLD's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ZLD's Return on Equity is forecast to be high in 3 years time


Discover growth companies